Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Cash Flow

v3.8.0.1
Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash Flows from Operating Activities:    
Net loss $ (6,620) $ (2,503)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 13 2
Stock-based compensation 487 209
Deferred CEO compensation 62 88
Change in fair value of warrant liability 2,753 0
Gain in settlement of liability (149) 0
Gain from expiration of warrants (1,238) 0
Other (9) 0
Changes in operating assets and liabilities:    
Prepaid expenses (518) (245)
Accounts payable and accrued expenses 285 (147)
Net Cash Used in Operating Activities (4,934) (2,596)
Cash Flows from Investing Activities:    
Purchase of fixed assets (12) (10)
Purchase paid for acquisition of Moleculin, LLC, net with cash acquired 0 (100)
Net Cash Used in Investing Activities (12) (110)
Cash Flows from Financing Activities:    
Proceeds from notes payable 0 165
Payments on note payable 0 (470)
Proceeds from exercise of warrants 3,808 0
Proceeds from sale of common stock units, net of cash stock issuance costs 4,867 9,167
Net Cash Provided by Financing Activities 8,675 8,862
Net change in cash and cash equivalents 3,729 6,156
Cash and cash equivalents, at beginning of period 5,007 28
Cash and cash equivalents, at end of period 8,736 6,184
Supplemental disclosures of cash flow information:    
Cash paid for interest 2 48
Cash paid for income taxes 0 0
Supplemental disclosure of non-cash investing and financing activities:    
Common stock issued for conversion of debt 302 342
Common stock issued for services provided 89 0
Common stock issued to acquire Moleculin, LLC $ 0 $ 9,774

Source